Bausch + Lomb Corporation (BLCO)

Executive Summary / Key Takeaways

• Financial Excellence Driving Structural Margin Expansion: Bausch + Lomb's Q4 2025 results—27% adjusted EBITDA growth on 7% constant currency revenue growth—signal a fundamental shift from growth-at-all-costs to profitable scaling, with management's new "financial excellence" pillar targeting 200 basis points of margin improvement through gross margin expansion and SG&A leverage.

• Dry Eye Market Dominance Creates Durable Growth Engine: With MIEBO and XIIDRA capturing the #1 and #2 positions in a market expected to nearly double within four years, BLCO has established a pharmaceutical franchise that grew 14% in Q4 2025 and is projected to exceed $600 million in peak sales for MIEBO alone, providing a high-margin, recurring revenue stream that diversifies beyond contact lenses.

• Surgical Resilience Validated Through Crisis Management: The March 2025 enVista IOL recall, initially a $65 million EBITDA headwind, became a testament to operational excellence as transparent communication and rapid remediation restored sales to pre-recall levels by Q4, building surgeon trust and positioning the segment for 10% underlying growth despite the temporary disruption.

• Capital Structure Optimization Reduces Financial Risk: Successful refinancing of $3.1 billion in debt to 2031 maturities, combined with a target investment-grade rating and improving cash flow conversion approaching 45%, materially reduces balance sheet risk while enabling continued investment in the 60+ project pipeline.

• BHC's 88% Ownership Creates Asymmetric Risk/Reward: The limited public float, while potentially depressing valuation multiples, represents a clear catalyst if Bausch Health (BHC) reduces its stake, with the stock trading at just 1.07x sales and 0.84x book value—significant discounts to pure-play eye care peers despite improving fundamentals.

Setting the Scene: The 170-Year-Old Eye Health Platform

Bausch + Lomb Corporation, founded in 1853 and headquartered in Vaughan, Ontario, has evolved from a traditional contact lens manufacturer into a comprehensive eye health platform spanning vision care, pharmaceuticals, and surgical devices. The company generates approximately $5.1 billion in annual revenue across three segments: Vision Care (57% of revenue), Pharmaceuticals (26%), and Surgical (17%). This integrated model creates multiple touchpoints with eye care professionals and consumers, enabling cross-selling opportunities and insulating the company from single-product dependencies that affect pure-play competitors.

The eye health industry benefits from powerful secular tailwinds that make it structurally attractive. An aging global population, increased screen time driving dry eye prevalence, and rising cataract surgery volumes create a market growing at mid-single-digit rates. Yet only one in ten dry eye patients currently receives prescription therapy, leaving substantial runway for penetration. This underpenetration transforms what could be a mature market into a growth opportunity, particularly for companies with the product portfolio and commercial infrastructure to educate and convert patients.

BLCO's competitive positioning reflects its hybrid nature. Unlike Alcon's (ALC) surgical dominance (49% market share) or CooperVision's (COO) contact lens specialization (25% share), BLCO competes across the entire eye health value chain. This breadth creates a unique value proposition—eye care practices can source lenses, pharmaceuticals, and surgical consumables from a single partner—but also means BLCO faces specialized competitors in each arena. The company's 170-year brand heritage provides trust and recognition that newer entrants cannot replicate, particularly in consumer products where LUMIFY has become the #1 OTC redness reliever with $221 million in 2025 revenue.

Technology, Products, and Strategic Differentiation: Building the Eye Health Ecosystem

BLCO's product strategy centers on transforming episodic transactions into continuous patient relationships through innovation across all three segments. In Vision Care, the company has outpaced industry growth for two consecutive years, with 9% average constant currency revenue growth versus mid-single-digit market growth. This outperformance demonstrates that BLCO's investments in daily silicone hydrogel (SiHy) lenses—up 28% in 2025—and the ULTRA monthly line are gaining share against Alcon and Johnson & Johnson's (JNJ) entrenched positions. The first external study for a new bioactive contact lens material meeting expectations increases the probability of a 2028 launch that could redefine comfort and oxygen permeability standards.

The Pharmaceutical segment represents BLCO's most significant transformation. The $1.75 billion XIIDRA acquisition in September 2023, combined with MIEBO's organic success, created a dry eye franchise that delivered $331 million in 2025 revenue. MIEBO's performance is particularly instructive: crossing 2 million prescriptions in January 2026, growing Q4 revenue 111% year-over-year to $112 million, and having its peak sales estimate raised to "exceed $600 million." MIEBO is the only FDA-approved treatment for the evaporative component of dry eye disease, giving it a clinical moat against competitors like Novartis's (NVS) TRYPTYR, which runs at just 20% of MIEBO's launch-aligned prescription volume despite similar market positioning. The tolerability advantage—MIEBO's immediate symptom relief versus TRYPTYR's 50% burning/stinging rate and delayed onset—creates a switching cost that drives the 134% net dollar retention-like expansion within existing prescribers.

In Surgical, the enVista IOL platform demonstrates how product innovation drives premium mix. Despite the recall, premium IOLs grew 26% in 2025, with enVista Envy capturing market share through its extended depth of focus technology. The upcoming enVista Beyond EDOF IOL and LuxLife full-range-of-vision IOL (approved in Europe May 2025) address the premium cataract segment where ASPs are 3-5x higher than monofocals. The seeLYRA femtosecond laser , with CE mark submission expected in February 2026, represents BLCO's entry into the equipment side of refractive surgery, competing directly with Alcon's dominant excimer platforms.

The pipeline's depth—over 60 projects globally—de-risks concentration. A novel alpha-2 agonist glaucoma medication that improves visual acuity (not just intraocular pressure) entering Phase 2 in November 2025 could create a first-in-class therapy. A myopia control lens completing recruitment with interim data expected early 2026 addresses the pediatric market where CooperVision's MiSight currently dominates. Each program represents a call option on market expansion.

Financial Performance & Segment Dynamics: Evidence of Platform Economics

BLCO's 2025 financial results provide evidence that the platform strategy is working. Full-year constant currency revenue growth of 6% (excluding the enVista recall) matched the company's planned CAGR through 2028 and outpaced market growth. More importantly, adjusted EBITDA margin expanded to 17.5% for the year and reached a record 23.5% in Q4, demonstrating operating leverage that validates the "financial excellence" pillar. This margin inflection shows that revenue growth is translating to profit growth at nearly 4x the rate, a relationship management projects will continue in 2026.

Segment performance reveals the engine of this leverage. Vision Care's $2.923 billion in 2025 revenue grew 6% with stable 29% segment profit margins, but the mix shift within the segment tells the real story. Contact lens revenue grew 7% overall, but daily SiHy lenses surged 28% while ULTRA monthly grew 9%. Daily lenses command higher ASPs and margins than legacy two-week lenses, and the 17% Q4 growth in this category indicates successful premiumization. The consumer business grew 5% for the year, but LUMIFY's 16% growth to $221 million and the dry eye portfolio's 14% growth to $436 million show that higher-margin pharmaceutical-grade OTC products are driving mix improvement.

The Pharmaceutical segment's transformation is even more pronounced. Revenue grew 6% to $1.284 billion, but the U.S. Branded Rx business grew 13% for the year and 21% in Q4, indicating accelerating momentum. MIEBO's $316 million in 2025 revenue represents 84% growth, while XIIDRA's $331 million is stabilizing after gross-to-net adjustments related to the Inflation Reduction Act. The segment's 20% profit margin in 2025 reflects investment in market access that should yield improved net pricing as gross-to-net steps down from the mid-70s to low-70s in 2026.

Surgical's recovery narrative is notable. The segment grew 10% excluding the enVista recall impact. The $65 million EBITDA hit from the recall was absorbed while maintaining segment profitability, and Q4's return to pre-recall sales levels—achieved through transparent communication and enhanced quality protocols—built surgeon trust that management expects to convert into share gains as monofocal contracts expire. Premium IOLs growing 26% while the base monofocal segment remained pressured shows BLCO is successfully migrating surgeons to higher-value products even during a crisis.

Cash flow dynamics support the margin expansion thesis. Adjusted free cash flow was $32 million for the full year, absorbing $349 million in capex and the enVista recall impact. The company's target of 50%+ cash flow conversion by 2028, with current conversion at 42%, signals that margin expansion will translate to free cash flow as capex intensity steps down to 5-6% of revenue in 2026. The December 2025 acquisition of a Mexico manufacturing facility for $75 million upfront unlocks capacity and expands margins by internalizing production that was previously outsourced.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance—$5.375 to $5.475 billion in revenue (5-7% constant currency growth) and $1.0 to $1.05 billion in adjusted EBITDA (19% margin at midpoint)—implies EBITDA growth of nearly 15%, or roughly 2.5x revenue growth. This relationship demonstrates the company's confidence in sustained operating leverage. The guidance assumes continued MIEBO momentum, XIIDRA pricing optimization, enVista share recapture, and successful launches of PreserVision AREDS3 and Blink Triple Care preservative-free, both shipping in early 2026.

The quarterly phasing—Q1 lowest, Q4 highest—will become more pronounced as the dry eye franchise grows, creating a seasonal pattern similar to pharmaceutical companies. This indicates a more predictable, recurring revenue base. Management's commentary that MIEBO's peak sales could "exceed $600 million" and that XIIDRA will see "mid-single digit" growth suggests the pharmaceutical segment could approach $1.5 billion in revenue by 2027, representing a higher-margin mix shift.

Execution risks center on three areas. First, the U.S. Generics business remains unpredictable and commodity-like, creating quarterly volatility. Second, tariff exposure—particularly reciprocal tariffs on U.S. exports to China—could pressure margins by an estimated 120 basis points in 2025, though management is evaluating mitigating levers including inventory stocking and in-house manufacturing. Third, competitive pressure in contact lenses from J&J's Acuvue and Alcon's Precision1 could slow BLCO's outperformance, particularly if daily SiHy growth decelerates from the current 28% pace.

The most significant execution variable is the enVista monofocal recovery. While premium IOLs have rebounded strongly, base monofocal contracts signed during the recall period won't expire until 2026-2027. Management's confidence in recapturing this business is significant because monofocal IOLs represent higher volume, and full recovery is necessary to achieve the segment's 10% underlying growth potential.

Risks and Asymmetries: What Could Break the Thesis

The BHC ownership overhang represents a visible risk. With approximately 88% ownership as of February 2026, the limited public float constrains institutional ownership and may depress valuation multiples. This likely holds the company back in terms of multiple expansion. The asymmetry is clear: if BHC reduces its stake, the stock could re-rate higher on increased liquidity, but until then, the overhang remains a factor.

Tariff policy creates margin risk. With approximately 120 basis points of potential adjusted EBITDA margin headwind in 2025, reciprocal tariffs on U.S.-to-China exports represent BLCO's largest exposure. The company's global manufacturing footprint provides flexibility, but the fluid policy environment means mitigation strategies may lag implementation. This introduces external volatility that could offset a portion of the planned margin improvement.

Competitive dynamics in the dry eye market could shift. Novartis's TRYPTYR benefits from the pharma giant's commercial infrastructure. If TRYPTYR gains formulary advantages or if a new entrant emerges with better efficacy, BLCO's #1 and #2 position could be challenged. MIEBO's 2 million prescriptions represent a fraction of the addressable market, showing both runway and vulnerability.

The surgical segment faces intense competitive pressure. Alcon's 49% market share and J&J's TECNIS platform create formidable barriers. While BLCO's handling of the enVista recall built trust, the "hangover" in monofocal contracts means competitors had a window to entrench relationships. If BLCO cannot recapture this business by 2027, the segment's growth trajectory would fall below the 10% underlying rate.

On the positive side, pipeline success could create meaningful upside. The alpha-2 agonist glaucoma medication, if Phase 2 data in November 2025 confirms visual acuity benefits, would be first-in-class with pricing power. The bioactive contact lens material, with a second external study planned and 2028 launch targeted, could command premium pricing in a market where comfort drives loyalty.

Valuation Context: Discounted Platform Value

At $15.37 per share, BLCO trades at an enterprise value of $10.32 billion, representing 2.02x TTM revenue and 16.95x TTM EBITDA. These multiples stand at discounts to pure-play eye care peers: Alcon trades at 3.87x revenue and 17.29x EBITDA, while Cooper Companies trades at 3.92x revenue and 14.79x EBITDA. The discount reflects both BLCO's conglomerate structure and the float overhang.

The company's balance sheet strength supports valuation. With net debt of 0.80x equity and a current ratio of 1.55, BLCO has liquidity to fund its $285 million 2026 capex plan and $371 million R&D investment. The absence of dividend payments signals management's priority is reinvesting in growth and deleveraging, appropriate for a company targeting investment-grade status.

Cash flow metrics provide additional context. The price-to-operating cash flow ratio of 19.28x reflects the current investment phase. With cash flow conversion progressing toward 45% in 2026 and a target of 50%+ by 2028, the ratio should compress as free cash flow grows. The company's $6.4 billion in cash and equivalents provides a strategic cushion.

Relative to peers, BLCO's 11.25% operating margin trails Alcon's 11.70% and lags Cooper's 20.78%. This margin gap represents the opportunity: if BLCO executes on its 200 basis points of planned margin improvement, it would approach Alcon's profitability while growing faster than the market. The trajectory toward positive returns as margins expand makes the current valuation appear conservative for a platform with 6% market-outpacing growth.

Conclusion: Platform Value vs. Structural Discount

Bausch + Lomb has evolved into a comprehensive eye health platform, with Q4 2025's margin inflection providing evidence that the strategy is working. The combination of MIEBO's $600 million peak sales potential, XIIDRA's pricing optimization, and the enVista surgical recovery creates a growth engine that should drive EBITDA growth at nearly 3x revenue growth through 2026. This operating leverage, coupled with debt refinancing and manufacturing optimization, positions BLCO for investment-grade metrics within two years.

The central thesis hinges on whether this operational improvement can overcome the structural discount created by BHC's 88% ownership. While the float overhang is not within management's control, the company's decision to formalize "financial excellence" as a strategic pillar addresses the valuation gap by demonstrating that spending drives growth or efficiency. Continued execution could force a re-rating even without BHC selling, while any reduction in the overhang would amplify returns.

For investors, the critical variables are MIEBO's prescription trajectory, enVista's monofocal share recapture, and tariff mitigation success. If BLCO delivers on its 19% EBITDA margin target in 2026 while maintaining 6% revenue growth, the stock's 2x revenue multiple will appear increasingly anomalous for a diversified eye health leader. The platform strategy has created multiple ways to win; now the financial results must prove it's worth a premium valuation.